Patent intelligence · US
US 11446397
Gene therapy vectors for treating heart disease
Gene therapy vectors for treating heart disease
Patent details — US 11446397
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 20, 2022
- Expiration
- Sep 15, 2042
- Applicant
- Tenaya Therapeutics, Inc.
- Claims
- 19
- CPC classes
- A61K, A61K38/00, A61K48/005, A61K48/0058
Quick answer
US 11446397 (Gene therapy vectors for treating heart disease) is held by Tenaya Therapeutics, Inc.. Status: granted. Granted Sep 20, 2022. Expires Sep 15, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Tenaya Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K38/00, A61K48/005, A61K48/0058, A61P, A61P9/00
More from Tenaya Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12312345
Fluoroalkyl-oxadiazoles and uses thereof
granted -
US 12201617
HDAC6 inhibitors for treatment of metabolic disease and HFpEF
granted -
US 12168778
Cardiac cell reprogramming with myocardin and ASCL1
granted -
US 12151001
Optimized expression cassettes for gene therapy
granted -
US 12104165
Adeno-associated virus with engineered capsid
granted -
US 11926622
Fluoroalkyl-oxadiazoles and uses thereof
granted -
US 11913012
Cardiac cell reprogramming with myocardin and ASCL1
granted -
US 11781156
Plakophillin-2 gene therapy methods and compositions
granted
Frequently asked questions
What is US patent 11446397?
US 11446397 (Gene therapy vectors for treating heart disease) is held by Tenaya Therapeutics, Inc.. Status: granted. Granted Sep 20, 2022. Expires Sep 15, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11446397?
Tenaya Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 13 pharmaceutical patents for this assignee.
When does US 11446397 expire?
Our index shows an expiration date of Sep 15, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.